Navigation Links
Fred Hutchinson Cancer Research Center and NSB POSTECH, Inc. to Collaborate on Development of New Class of Proteomic Microarrays
Date:3/20/2008

SEATTLE, March 20 /PRNewswire/ -- Fred Hutchinson Cancer Research Center (FHCRC) and NSB POSTECH, Inc. (NSB) have reached a collaboration agreement to coordinate their efforts and to determine the efficacy of the NSB's NanoCones surface technology in creating high quality proteomic microarrays to be used in the study of human diseases.

NSB is a South Korean biotech company which possesses a proprietary microarray technology and a great deal of expertise in nano-scale controlled surface chemistry. NSB has agreed to fund the collaboration.

Announced today, this collaboration will involve a comparison of slides created with NSB's newly developed NanoCones surface technology and the current industry standard.

"This is the first time a Korean biotech company has had an opportunity to collaborate with a major U.S.-based cancer research center. We are very thrilled to be working with scientists at the Hutchinson Center," said Dr. Joon Won Park, president of NSB and one of the inventors of the NanoCones technology.

"We are excited about the preliminary data that has been generated when antibodies were arrayed using the NanoCones technology. We hope this will make our antibody arrays more sensitive and accurate," said Dr. Paul Lampe, member of the Hutchinson Center's Public Health Sciences Division and associate program head of molecular diagnostics.

Antibody or protein microarrays are glass microscope slides onto which very small amounts of thousands of different antibodies or proteins have been affixed at distinct locations. Antibody microarrays can be used to simultaneously determine the level of each antibody's specific binding partner in complex mixtures such as blood so thousands of different assays can be performed with small amounts of sample.

At Fred Hutchinson Cancer Research Center, interdisciplinary teams of world-renowned scientists and humanitarians work together to prevent, diagnose and treat cancer, HIV/AIDS and other diseases. Hutchinson Center researchers, including three Nobel laureates, bring a relentless pursuit and passion for health, knowledge and hope to their work and to the world. For more information, visit http://www.fhcrc.org.

NSB POSTECH, Inc. is a South Korea based Biotech Company specializing in nano-surface technology for genomic and proteomic microarrays. NSB's mission is to detect and prevent disease. NanoCones technology research was funded with support from POSCO, Korea's world-renowned steel manufacturer and POSTECH, one of Asia's leading Science and Technology Universities. For more information, visit http://www.nsbpostech.com.


'/>"/>
SOURCE NSB POSTECH, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Johns Hopkins to add Elekta Synergy S(R) to Cancer Treatment Lineup
3. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
4. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
5. GlaxoSmithKline Recognizes University of Michigans Dr. Daniel F. Hayes as the First Recipient of the Gianni Bonadonna Breast Cancer Award
6. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
7. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
8. Novel Technology Breaks Through Cancer Pain
9. ONCOSCIENCE AG, THE EUROPEAN PARTNER OF YM BIOSCIENCES, ANNOUNCES COMPLETION OF PATIENT ENROLLMENT IN PHASE III BRAIN CANCER TRIAL OF NIMOTUZUMAB
10. Pharmion and MethylGene Announce Collaboration to Develop Sirtuin Inhibitors as Anti-Cancer Agents
11. YM BIOSCIENCES, EUROPEAN PARTNER, ONCOSCIENCE AG, ANNOUNCES INITIATION OF ADVANCED NIMOTUZUMAB TRIALS IN ADULT GLIOMA AND PANCREATIC CANCER
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... 11, 2016   BioInformant announces the February ... Research Products, Opportunities, Tools, and Technologies – Market Size, ... The first and ... cell industry, BioInformant has more than a decade of ... market, by stem cell type. This powerful 175 page ...
(Date:2/11/2016)... ... February 11, 2016 , ... Global ... treatment clinic in Quito, Ecuador. The new facility will provide advanced protocols and ... from around the world. , The new GSCG clinic is headed by ...
(Date:2/10/2016)... -- The Maryland House of Delegates and House Speaker ... Maryland School of Medicine Dean E. Albert Reece ... System President and CEO Robert Chrencik , MBA, ... given to the public by the leader of the ... and Mr. Chrencik for their contributions to our statewide ...
(Date:2/10/2016)... New York (PRWEB) , ... ... ... Inc. (NASDAQ: REGN) today announced that it has joined the Human Vaccines ... immunotherapies for infectious diseases and cancer. , The Human Vaccines Project ...
Breaking Biology Technology:
(Date:1/28/2016)... Synaptics (NASDAQ: SYNA ), a leading developer of human interface ... 31, 2015. --> --> ... percent compared to the comparable quarter last year to $470.5 million. ... million, or $0.93 per diluted share. --> ... of fiscal 2016 grew 9 percent over the prior year period ...
(Date:1/25/2016)... BELL, Pa. , Jan. 25, 2016   Unisys Corporation ... recognition system at John F. Kennedy (JFK) International Airport, ... Border Protection (CBP) identify imposters attempting to enter ... do not belong to them. pilot testing of ... out initially at three terminals at JFK during January 2016. ...
(Date:1/22/2016)... January 22, 2016 ... addition of the  "Global Behavioral Biometric ... --> http://www.researchandmarkets.com/research/4lmf2s/global_behavioral ) has ... Behavioral Biometric Market 2016-2020"  report to ... and Markets ( http://www.researchandmarkets.com/research/4lmf2s/global_behavioral ) has announced ...
Breaking Biology News(10 mins):